PAUL BARBERA: Open Payments
NPI 1053459487 · SPARROWS POINT, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$546 in 22 payments from 8 companies in 2025. Trend: 2023 $186 · 2024 $212 · 2025 $546
Food & beverage: $546
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $159 |
| Astellas Pharma US Inc | 6 | $127 |
| Novo Nordisk Inc | 4 | $84 |
| PFIZER INC. | 2 | $46 |
| Lilly USA, LLC | 2 | $42 |
| Exact Sciences Corporation | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $32 |
| Amgen Inc. | 1 | $17 |
Products named: BREZTRI, Veozah, ELIQUIS, MOUNJARO, Rybelsus, The Cologuard Plus Collection Kit, TRELEGY ELLIPTA, Ozempic.
Industry payments across MD — which companies pay providers there.
